Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Antares doses first patient in Phase III testosterone deficiency study

Antares Pharma, Inc., a provider of parenteral pharmaceutical products, has dosed the first patient in a double-blind, multiple-dose, Phase III study to evaluate the efficacy and safety of QuickShot Testosterone, or QS T, administered subcutaneously once each week to testosterone-deficient adult males.

Published By MarketLine
25 Jul 2014
NewsWire
NewsWire

Cubist Pharmaceuticals Q2 net income up

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, has reported that net income for the second quarter ended June 30, 2014 was $24.03 million, or $0.3 per diluted share, compared to $15.24 million, or $0.23 per diluted share, for the second quarter ended June 30, 2013.

Published By MarketLine
25 Jul 2014
NewsWire
NewsWire

Synta announces Phase III extension of acute myeloid leukemia study

Synta Pharmaceuticals Corp., a biopharmaceutical company, has announced the advancement of ganetespib into the Phase III extension of the AML LI-1 trial for acute myeloid leukemia, or AML, and high-risk myelodysplastic syndrome, or MDS.

Published By MarketLine
25 Jul 2014
NewsWire
NewsWire

Boston Scientific launches new intravascular imaging system

Boston Scientific Corporation, a medical technology company, has launched the new POLARIS Imaging System for intravascular imaging.

Published By MarketLine
25 Jul 2014
NewsWire
NewsWire

Synergy completes patient enrollment for Phase II OIC trial

Synergy Pharmaceuticals Inc., a biopharmaceutical company, has completed patient enrollment for its Phase II trial of SP-333, the company's next-generation uroguanylin analog, in patients with opioid-induced constipation, or OIC.

Published By MarketLine
25 Jul 2014
NewsWire
NewsWire

Hanmi and Actavis enter into collaboration for arthritis pain treatment in US

Hanmi Pharm. Co. Ltd. and Actavis plc, a developer of generic drugs, have entered into 12 years collaboration for Hyalrheuma, hyaluronic acid injection for arthritis pain treatment, in US market.

Published By MarketLine
25 Jul 2014
NewsWire
NewsWire

Alkermes initiates Phase I multiple sclerosis study

Alkermes plc, a biopharmaceutical company, has initiated a Phase I clinical study of ALKS 8700, a novel monomethyl fumarate, or MMF, molecule in development for the treatment of multiple sclerosis.

Published By MarketLine
25 Jul 2014
NewsWire
NewsWire

Covidien announces group president appointment

Covidien plc, a healthcare provider, has announced the appointment of Bryan Hanson, group president of medical devices & US, to the newly created position of group president of the company, effective October 1, 2014.

Published By MarketLine
25 Jul 2014
NewsWire
NewsWire

Aetna appoints new board member

Aetna, Inc., a managed health care company, has appointed Olympia Snowe, former US senator, to its board of directors.

Published By MarketLine
25 Jul 2014
NewsWire
NewsWire

Centene reports higher Q2 net earnings, provides annual outlook

Centene Corporation, a multi-line healthcare enterprise, has reported that net earnings attributable to the company's common shareholders for the second quarter ended June 30, 2014 were $48.86 million, or $0.82 per diluted share, compared to $39.48 million, or $0.7 per diluted share, for the second quarter ended June 30, 2013. The company expects premium and service revenues to be in the range of $15 billion to $15.5 billion for 2014.

Published By MarketLine
25 Jul 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.